LFMD
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades at a low multiple of sales, but high multiple of book value.
- Low P/S ratio (0.86)
- Low Forward P/E (7.80)
- High Price/Book (7.00)
- Earnings instability makes P/E unreliable
Growth metrics are in freefall, contradicting analyst target prices.
- YoY Revenue Growth -27.10%
- Q/Q Revenue Growth -88.98%
Long-term trend is overwhelmingly negative.
- Historical periods of EPS beats in 2023-2024
- 5Y Change -74.2%
- Recent 6M Change -43.8%
Low debt is the only saving grace; operational health is critical.
- Low Debt/Equity (0.27)
- Piotroski F-Score 2/9
- ROE -131.16%
- ROA -6.54%
Non-dividend paying growth stock.
- No dividend paid
- 0/100 strength score
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for LFMD and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
LFMD
LifeMD, Inc.
Primary
|
-74.2% | +107.8% | -30.3% | -43.8% | -14.5% | -1.1% |
|
DERM
Journey Medical Corporation
Peer
|
-50.0% | +251.1% | -28.9% | -34.4% | -38.3% | +5.5% |
|
ACH
Accendra Health, Inc.
Peer
|
-92.8% | -89.2% | -85.8% | -73.2% | -22.1% | -16.3% |
|
HRTX
Heron Therapeutics, Inc.
Peer
|
-94.8% | -68.8% | -53.1% | -33.4% | -12.1% | +6.6% |
|
INGN
Inogen, Inc.
Peer
|
-88.6% | -52.4% | -10.6% | -22.4% | +1.6% | +1.9% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
LFMD
LifeMD, Inc.
|
BEARISH | $166.47M | - | -131.2% | 7.4% | $3.47 | |
|
DERM
Journey Medical Corporation
|
BEARISH | $164.62M | - | -44.0% | -18.5% | $4.95 | Compare |
|
ACH
Accendra Health, Inc.
|
BEARISH | $163.2M | - | -196.4% | -12.4% | $2.11 | Compare |
|
HRTX
Heron Therapeutics, Inc.
|
BEARISH | $160.82M | - | -% | -13.0% | $0.85 | Compare |
|
INGN
Inogen, Inc.
|
BEARISH | $172.38M | - | -12.4% | -6.5% | $6.33 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-30 | PISANO CHRISTOPHER A | Officer | Stock Award | 200,000 | - |
| 2025-12-09 | FRIEDEMAN JESSICA | Officer | Sale | 15,000 | $54,158 |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning LFMD from our newsroom.